Agenus Inc. (AGEN)
NASDAQ: AGEN · Real-Time Price · USD
3.290
+0.190 (6.13%)
At close: Mar 16, 2026, 4:00 PM EDT
3.400
+0.110 (3.34%)
After-hours: Mar 16, 2026, 5:51 PM EDT
Agenus Revenue
In the year 2025, Agenus had annual revenue of $114.20M with 10.37% growth. Agenus had revenue of $34.20M in the quarter ending December 31, 2025, with 27.45% growth.
Revenue (ttm)
$114.20M
Revenue Growth
+10.37%
P/S Ratio
1.18
Revenue / Employee
$338,066
Employees
316
Market Cap
126.33M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 114.20M | 10.73M | 10.37% |
| Dec 31, 2024 | 103.46M | -52.85M | -33.81% |
| Dec 31, 2023 | 156.31M | 58.29M | 59.47% |
| Dec 31, 2022 | 98.02M | -197.64M | -66.85% |
| Dec 31, 2021 | 295.67M | 207.50M | 235.34% |
| Dec 31, 2020 | 88.17M | -61.88M | -41.24% |
| Dec 31, 2019 | 150.05M | 113.26M | 307.92% |
| Dec 31, 2018 | 36.78M | -6.09M | -14.21% |
| Dec 31, 2017 | 42.88M | 20.30M | 89.95% |
| Dec 31, 2016 | 22.57M | -2.24M | -9.04% |
| Dec 31, 2015 | 24.82M | 17.84M | 255.67% |
| Dec 31, 2014 | 6.98M | 3.93M | 129.13% |
| Dec 31, 2013 | 3.05M | -12.92M | -80.92% |
| Dec 31, 2012 | 15.96M | 13.20M | 479.17% |
| Dec 31, 2011 | 2.76M | -603.84K | -17.97% |
| Dec 31, 2010 | 3.36M | 25.17K | 0.75% |
| Dec 31, 2009 | 3.33M | 683.36K | 25.78% |
| Dec 31, 2008 | 2.65M | -2.90M | -52.25% |
| Dec 31, 2007 | 5.55M | 4.86M | 702.20% |
| Dec 31, 2006 | 692.14K | 62.16K | 9.87% |
| Dec 31, 2005 | 629.98K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Codexis | 70.39M |
| Sangamo Therapeutics | 32.88M |
| Innate Pharma | 14.84M |
| Fate Therapeutics | 6.65M |
| Ovid Therapeutics | 6.61M |
| Rani Therapeutics Holdings | 1.20M |
| Cardiff Oncology | 593.00K |
AGEN News
- 10 hours ago - Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized - Business Wire
- 6 days ago - Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs - Business Wire
- 12 days ago - Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update - Business Wire
- 25 days ago - Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL - Business Wire
- 5 weeks ago - Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors - Business Wire
- 6 weeks ago - Agenus Inc. (AGEN) Discusses Zydus Collaboration, Global Manufacturing Expansion, and Patient Access Initiatives Transcript - Seeking Alpha
- 7 weeks ago - Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab - Business Wire
- 7 weeks ago - Agenus to Host First 2026 Stakeholder Webcast - Business Wire